| Date | Title | Description |
| 03.04.2024 | LifeArc Ventures Investment Principal, Chris Baker, reflects on the highlights from AUTM23 | The AUTM conference was the first society/association event I’ve attended where diversity and inclusion were being addressed so effectively. Refreshingly, the conversation has progressed from simple numbers to people actively feeling empowe... |
| 03.04.2024 | Clare Terlouw, Head of LifeArc Ventures, talks about the LifeArc co-founded company RQ Bio licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-... | - |
| 03.04.2024 | Clare Terlouw, Head of LifeArc Ventures, talks about the acquisition of portfolio company, Ducentis BioTherapeutics by Arcutis Biotherapeutics for up to $400 million | - |
| 03.04.2024 | Kovilen Sawmynaden, Senior Principal Scientist at LifeArc, explains the science behind RQ Bio’s monoclonal antibodies against SARS-CoV-2 – | - |
| 26.03.2024 | Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines | Castleford and London, UK, 26th March 2024: Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.
Under the agreement, Closed Loop Medicine – a leading Tech... |
| 26.03.2024 | Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines | Castleford and London, UK, 26th March 2024: Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.
Under the agreement, Closed Loop Medicine – a leading TechB... |
| 18.03.2024 | RQ Biotechnology Ltd. Celebrates Milestone with Grant of GB Patent Covering its Licensed Clinical-Stage Antibody for the Prevention and Treatment of COVID-19 | RQ Biotechnology Ltd. (“RQ”) a leader in the discovery of antibodies for the treatment of infectious disease, today announced that the UK Intellectual Property Office (IPO) has granted its patent application covering the company’s monoclona... |
| 18.03.2024 | RQ Biotechnology Ltd. Celebrates Milestone with Grant of GB Patent Covering its Licensed Clinical-Stage Antibody for the Prevention and Treatment of COVID-19 | RQ Biotechnology Ltd. (“RQ”) a leader in the discovery of antibodies for the treatment of infectious disease, today announced that the UK Intellectual Property Office (IPO) has granted its patent application covering the company’s monoclona... |
| 15.03.2024 | Cumulus Neuroscience Announces First Patient Enrolled in AccelADx™ Electroencephalogram (EEG) Study for Early Detection of Alzheimer’s Dementia | NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer’s Dementia
BELFAST, Northern Ireland and CAMBRIDGE, Mass.—March 14, 2024— Cumulus Neuroscience (Cumulus; The Company), a global digital health com... |
| 15.03.2024 | Cumulus Neuroscience Announces First Patient Enrolled in AccelADx™ Electroencephalogram (EEG) Study for Early Detection of Alzheimer’s Dementia | NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer’s Dementia
BELFAST, Northern Ireland and CAMBRIDGE, Mass.—March 14, 2024— Cumulus Neuroscience (Cumulus; The Company), a global digital health company focu... |
| 12.03.2024 | Cumulus Neuroscience Presents Data at AD/PD™ 2024 Annual Meeting | Data presented at the 2024 Alzheimer’s & Parkinson’s Diseases (AD/PD) Conference provides validation of two novel assessments in the Cumulus Neuroscience platform, suitable for at-home use by patients, in terms of sensitivity to change ... |
| 12.03.2024 | Cumulus Neuroscience Presents Data at AD/PD™ 2024 Annual Meeting | Data presented at the 2024 Alzheimer’s & Parkinson’s Diseases (AD/PD) Conference provides validation of two novel assessments in the Cumulus Neuroscience platform, suitable for at-home use by patients, in terms o... |
| 08.02.2024 | Closed Loop Medicine demonstrates application of novel drug plus software product for personalized treatment of hypertension | London, UK, Thursday 8th February 2024: Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publicatio... |
| 08.02.2024 | Closed Loop Medicine demonstrates application of novel drug plus software product for personalized treatment of hypertension | London, UK, Thursday 8th February 2024: Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publicatio... |
| 01.02.2024 | Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO | 1 February 2024 – Cambridge, UK – Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced today that Dr A ...... |
| 01.02.2024 | Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO | 1 February 2024 – Cambridge, UK – Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced today that Dr Arndt Schottelius has been... |
| 25.01.2024 | Six new investments, portfolio progress and an expanding investment team | Clare Terlouw, Head of LifeArc Ventures, said: “Our portfolio of investments expanded during the year and despite challenging financing conditions in the sector we were pleased to invest in six new companies and to continue to support our e... |
| 25.01.2024 | Six new investments, portfolio progress and an expanding investment team | Clare Terlouw, Head of LifeArc Ventures, said: “Our portfolio of investments expanded during the year and despite challenging financing conditions in the sector we were pleased to invest in six new companies and to continue to support our e... |
| 07.11.2023 | AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations | London, UK; November 6, 2023 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that the U.S. Food and Drug Administrat... |
| 07.11.2023 | AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations | London, UK; November 6, 2023 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that the U.S. Food and Drug Administrat... |
| 25.10.2023 | Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting | Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data at the Clinical Trials on Alzheimer’s Disease (CTAD) Annua... |
| 25.10.2023 | Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting | Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient car ... |
| 10.10.2023 | AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations | London, UK; October 10, 2023 — AviadoBio, a pioneering gene therapy company developing and delivering transformative medicines for neurodegenerative disorders, today announced that it has initiated the Phase 1/2 ASPIRE-FTD clinical study of... |
| 10.10.2023 | AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations | London, UK; October 10, 2023 — AviadoBio, a pioneering gene therapy company developing and delivering transformative medicines for neurodegenerative disorders, today announced that it has initiated the Phase 1/2 ASPIRE-FTD clinical study of... |
| 22.09.2023 | Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors | Cambridge, UK – 21 September 2023 – Today, Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced the appointment of senior indus... |
| 22.09.2023 | Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors | Cambridge, UK – 21 September 2023 – Today, Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced the appointment of senior indus... |
| 04.08.2023 | Ozlo Sleep Emerges from Stealth and Unveils Flagship Product Ozlo Sleepbuds® | BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Ozlo Sleep (Ozlo), a science-driven sleep and audio technology company, emerged from stealth today w ... |
| 04.08.2023 | Ozlo Sleep Emerges from Stealth and Unveils Flagship Product Ozlo Sleepbuds® | BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Ozlo Sleep (Ozlo), a science-driven sleep and audio technology company, emerged from stealth today with plans to launch Ozlo Sleepbuds®, a revolutionary headphone designed specifically for sleep. Ozl... |
| 18.07.2023 | Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved da... |
| 18.07.2023 | Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digit ... |
| 13.07.2023 | Cumulus Neuroscience Announces Research Collaboration with the Universities of Bath and Bristol on Development of Breakthrough Test for Early Detection of Alzheimer’s Dementia | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 13, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved da... |
| 13.07.2023 | Cumulus Neuroscience Announces Research Collaboration with the Universities of Bath and Bristol on Development of Breakthrough Test for Early Detection of Alzheimer’s Dementia | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 13, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digit ... |
| 12.07.2023 | Cumulus Neuroscience Presents Key Data at the 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digit ... |
| 12.07.2023 | LifeArc Ventures Invests in Affect Therapeutics $16 million Series A to Deliver Next Generation Addiction Recovery | McLean, VA, July 12, 2023 – Affect Therapeutics (“Affect”), a company reimagining addiction treatment for the digital age ... |
| 12.07.2023 | LifeArc Ventures Invests in Affect Therapeutics $16 million Series A to Deliver Next Generation Addiction Recovery | McLean, VA, July 12, 2023 – Affect Therapeutics (“Affect”), a company reimagining addiction treatment for the digital age, today announces a $16 million Series A led by TechBio-focused ARTIS Ventures with additional participation from previ... |
| 12.07.2023 | Cumulus Neuroscience Presents Key Data at the 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved da... |
| 11.07.2023 | Cumulus Neuroscience to Present Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 11, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digit ... |
| 11.07.2023 | Cumulus Neuroscience to Present Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 11, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved da... |
| 07.07.2023 | Cumulus Neuroscience to Present Data at 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 6, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The ... |
| 07.07.2023 | Cumulus Neuroscience to Present Data at 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) | BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 6, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved dat... |
| 01.06.2023 | Cumulus Neuroscience LandsCoveted iF Design and Red DotAwards for Innovative At-Home EEGDevice | Used to Help Accelerate the Study and Development of Precision CNS Medicines, the Cumulus EEG Headset AttractsAccolades from Prestigious iF Design Award and International Red Dot Competitions
BELFAST, Northern Ireland and CAMBRIDGE, Mass.,... |
| 01.06.2023 | Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning,First-In-Class NeurophysiologyPlatform for At-Home Use | User-friendly electroencephalogram (EEG) synced device enables self-directed use and generates clinical-grade data forremote physician review.
Leadership team expands with appointment of industry veteran Tina Sampath as Chief Commercial Off... |
| 01.06.2023 | Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning,First-In-Class NeurophysiologyPlatform for At-Home Use | User-friendly electroencephalogram (EEG) synced device enables self-directed use and generates clinical-grade data forremote physician review.
Leadership team expands with appointment of industry veteran Tina Sampath as Chief Commercial Of... |
| 01.06.2023 | Cumulus Neuroscience LandsCoveted iF Design and Red DotAwards for Innovative At-Home EEGDevice | Used to Help Accelerate the Study and Development of Precision CNS Medicines, the Cumulus EEG Headset AttractsAccolades from Prestigious iF Design Award and International Red Dot Competitions
BELFAST, Northern Ireland and CAMBRIDGE, Mass., ... |
| 18.05.2023 | Closed Loop Medicine and Pharmanovia enter a co-development partnership for precision medicine combination therapeutics | London and Basildon, UK, 17 May 2023: Closed Loop Medicine Ltd, a leading TechBio company, developing combination prescription drug plus software therapy products that enable personalized dose optimization, and Pharmanovia, a global pharmac... |
| 18.05.2023 | Closed Loop Medicine and Pharmanovia enter a co-development partnership for precision medicine combination therapeutics | London and Basildon, UK, 17 May 2023: Closed Loop Medicine Ltd, a leading TechBio company, developing combination prescription drug plus software therapy products that enable personalized dose optimization, and Pharmanovia, a global pharmac... |
| 10.05.2023 | Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning, First-In-Class Neurophysiology Platform for At-Home Use | Cumulus Neuroscience is very proud and excited to announce that our novel, award-winning dry-sensor EEG headset, has been granted 510(k) clearance from the United States Food and Drug Administration (FDA). This represents the second medical... |
| 10.05.2023 | Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning, First-In-Class Neurophysiology Platform for At-Home Use | Cumulus Neuroscience is very proud and excited to announce that our novel, award-winning dry-sensor EEG headset, has been granted 510(k) clearance from the United States Food and Drug Administration (FDA). This represents the second medical... |
| 19.04.2023 | Maxion Therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “hard-to-treat” autoimmune diseases | Cambridge, UK – 19 April 2023 – Biotechnology company Maxion Therapeutics (‘Maxion’) today announced it has been awarded a prestigious GBP £2 million grant from innovate uij as part of its Biomedical Catalyst 2022 Round 2: lndustrvd
ied R&... |
| 19.04.2023 | Maxion Therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “hard-to-treat” autoimmune diseases | Cambridge, UK – 19 April 2023 – Biotechnology company M ... |
| 12.04.2023 | Cumulus Neuroscience ExpandsDevelopment Support of NovelPrecision CNS Therapeutics | BELFAST, Northern Ireland and CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; TheCompany), a global digital health company focused on advancing neuroscience clinical trials and patient care throughim... |
| 12.04.2023 | Cumulus Neuroscience ExpandsDevelopment Support of NovelPrecision CNS Therapeutics | BELFAST, Northern Ireland and CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ — Cumulus Neuroscience (Cumulus; TheCompany), a global digital health company focused on advancing neuroscience clinical trials and patient care throughimproved dat... |
| 15.02.2023 | LifeArc Ventures invests in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases | LONDON, UK, 15 February 2023 — LifeArc Ventures, the investment arm of LifeArc, today announced its participation in a USD $16 million (GBP £13 million) Series A financing for Maxion Therapeutics. The funds will be used to support... |
| 15.02.2023 | LifeArc Ventures invests in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases | LONDON, UK, 15 February 2023 — LifeArc Ventures, the investment arm of LifeArc, today announced its participation in a USD $16 million (GBP £13 million) Series A financing for Maxion Therapeutics. The funds will be used to support the devel... |
| 10.02.2023 | Cumulus Neuroscience appoints SiggiSaevarsson as COO | He has occupied senior management roles and been on the board of directors forseveral high-growth start-ups, as well as working directly for Intel Corporation, Nokia, OpenWave and other telecoms technology companies. He has a degree in Comp... |
| 10.02.2023 | Cumulus Neuroscience appoints SiggiSaevarsson as COO | He has occupied senior management roles and been on the board of directors forseveral high-growth start-ups, as well as working directly for Intel Corporation, Nokia, OpenWave and other telecoms technology companies. He has a degree in Comp... |
| 09.02.2023 | RQ Bio Strengthens Board with Industry-leading Infectious Disease Experts Joining as Non- Executive Directors | LONDON, UK, 9 February 2023 — RQ Bio is scaling up at speed, with the appointment of Non- Executive Directors, Dr W. Ripley (“Rip”) Ballou and Dr Jacques Cholat to its Board of Directors. Both new Non-Executive Directors have exte... |
| 09.02.2023 | RQ Bio Strengthens Board with Industry-leading Infectious Disease Experts Joining as Non- Executive Directors | LONDON, UK, 9 February 2023 — RQ Bio is scaling up at speed, with the appointment of Non- Executive Directors, Dr W. Ripley (“Rip”) Ballou and Dr Jacques Cholat to its Board of Directors. Both new Non-Executive Directors have extensive scie... |
| 01.02.2023 | Cumulus Neuroscience Expands ExecutiveTeam, Supporting Biopharma BusinessGrowth | We are delighted to announce the appointment of two biopharma industry experts,expanding our leadership bench and reflecting our growth in the biopharma space.Shani Waninger, Ph.D. , takes the helm as Vice President of BioPharma Business De... |
| 01.02.2023 | LifeArc Ventures – strong performance in 2022 & sustained investment in innovation | LONDON, UK, 1 February 2023 — LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio.
Clare Terlouw, Head of LifeArc Ventures, said: “Our team has had... |
| 01.02.2023 | LifeArc Ventures – strong performance in 2022 & sustained investment in innovation | LONDON, UK, 1 February 2023 — LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, today provides an update on its portfolio.
Clare Terlouw, Head of LifeArc Ventures, said: “Our tea... |
| 01.02.2023 | Cumulus Neuroscience Expands ExecutiveTeam, Supporting Biopharma BusinessGrowth | We are delighted to announce the appointment of two biopharma industry experts,expanding our leadership bench and reflecting our growth in the biopharma space.Shani Waninger, Ph.D. , takes the helm as Vice President of BioPharma Busin ... |
| 15.11.2022 | LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients | LONDON, UK – LifeArc Ventures, the investment arm of LifeArc, today announced its participation in a Seed investment in Surgery Hero, formerly Sapien Health Limited. Headquartered in London, Surgery Hero is a digital clinic that help ... |
| 15.11.2022 | LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients | LONDON, UK – LifeArc Ventures, the investment arm of LifeArc, today announced its participation in a Seed investment in Surgery Hero, formerly Sapien Health Limited. Headquartered in London, Surgery Hero is a digital clinic that helps peopl... |
| 21.09.2022 | Cumulus Neuroscience appoints digitalhealth and pharmaceutical executive AmanBhatti, MD as Chief Executive Officer | Cumulus Neuroscience has appointed Aman Bhatti, MD, as Chief Executive Officer(CEO). Dr. Bhatti, a noted digital health executive with experience launching andscaling world-renowned consumer healthcare brands, joins Cumulus as theCompany sh... |
| 21.09.2022 | Cumulus Neuroscience appoints digitalhealth and pharmaceutical executive AmanBhatti, MD as Chief Executive Officer | Cumulus Neuroscience has appointed Aman Bhatti, MD, as Chief Executive Officer(CEO). Dr. Bhatti, a noted digital health executive with experience launching andscaling world-renowned consumer healthcare brands, joins Cumulus as theCompany sh... |
| 08.09.2022 | LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million | LONDON, UK, 08 September 2022 — LifeArc today announced that its portfolio company Ducentis BioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, has been ... |
| 08.09.2022 | LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million | LONDON, UK, 08 September 2022 — LifeArc today announced that its portfolio company Ducentis BioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, has been ... |
| 10.08.2022 | New study highlights superior efficacy of at-home dry EEG assessment compared to lab-based monitoring | Cumulus Neuroscience announces positive results from a new study evaluating thevalidity of using its dry-electroencephalogram (EEG) headset and gamifiedcognitive tasks for unsupervised home-based measurement of cognition, with at-home EEG m... |
| 10.08.2022 | New study highlights superior efficacy of at-home dry EEG assessment compared to lab-based monitoring | Cumulus Neuroscience announces positive results from a new study evaluating thevalidity of using its dry-electroencephalogram (EEG) headset and gamifiedcognitive tasks for unsupervised home-based measurement of cognition, with at-home EEG m... |
| 25.05.2022 | Cumulus Neuroscience commences clinicalstudies of digital biomarker platform indegenerative neurological diseases | Brian Murphy, Cumulus Neuroscience’s Chief Scientific Officer, said: “Currentstandard measurement tools for dementia, such as clinician administered scales,only give a snapshot in an atypical environment and can suffer from day-to-dayvariat... |
| 25.05.2022 | Cumulus Neuroscience commences clinicalstudies of digital biomarker platform indegenerative neurological diseases | Brian Murphy, Cumulus Neuroscience’s Chief Scientific Officer, said: “Currentstandard measurement tools for dementia, such as clinician administered scales,only give a snapshot in an atypical environment and can suffer from day-to-dayvariat... |
| 17.05.2022 | LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2 | LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has signed a licensing agreement with AstraZeneca PLC (AZN). Under the terms of the agreement, RQ Bio has granted AstraZeneca an exclusive worldwide licenc... |
| 17.05.2022 | LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2 | LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has signed a licensing agreement with AstraZeneca PLC (AZN). Under the terms of the agreement, RQ Bio has granted AstraZeneca an exclusive worldwide licenc... |
| 02.12.2021 | LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases | Pioneering gene therapy company AviadoBio’s unique gene therapy platform targeting therapy to the right areas of the nervous system, and could help to develop transformative new treatments for patients with incurable and debilitating illnes... |
| 02.12.2021 | LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases | Pioneering gene therapy company AviadoBio’s unique gene therapy platform targeting therapy to the right areas of the nervous system, and could help to develop transformative new treatments for patients with incurable and debilitating illnes... |
| 16.11.2021 | LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science | Today, we reinforce our commitment to transform the lives of patients as we announce our new strategy which sets our direction and priorities until 2030.
We plan to spend up to £1.3 billion over the period to 2030 – that’s double our avera... |
| 16.11.2021 | LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science | Today, we reinforce our commitment to transform the lives of patients as we announce our new strategy which sets our direction and priorities until 2030. |
| 04.11.2021 | 10 new data-driven health companies selected for KQ Labs accelerator programme | - |
| 04.11.2021 | 10 new data-driven health companies selected for KQ Labs accelerator programme | - |
| 03.11.2021 | LifeArc invests in company developing personalised drug and digital combination treatments | The deal was led by Ananda Impact Ventures and BGF, and involved a strong syndicate of investors including LifeArc, |
| 03.11.2021 | LifeArc invests in company developing personalised drug and digital combination treatments | The deal was led by Ananda Impact Ventures and BGF, and involved a strong syndicate of investors including LifeArc, Longwall, Meltwind, IQ Capital, Downing Ventures and Cambridge Angels.
This new investment will enable the company to devel... |
| 25.10.2021 | Three new Trustees bring more skills and experience to LifeArc | A very warm welcome to three new Trustees who have joined our Board.
Sue Wallcraft, Ian Nicholson and Dr Ian Gilham bring vital skills and experience to help us work towards our new strategy. We are looking forward to working closely with ... |
| 25.10.2021 | Three new Trustees bring more skills and experience to LifeArc | A very warm welcome to three new Trustees who have joined our Board.
Sue Wallcraft, Ian Nicholson and Dr Ian Gilham bring vital skills and experience to help us work towards our new strategy. We are looking forward to working closely with t... |
| 04.05.2021 | LifeArc invests in Cumulus Neuroscience | Life Arc announces it has participated in a £6 million financing round into Cumulus Neuroscience, formerly known as BrainWaveBank. The funding is led by Dementia Discovery Fund (DDF)/SV Health investors and supported by the UK Future Fund.
... |
| 04.05.2021 | LifeArc invests in Cumulus Neuroscience | Life Arc announces it has participated in a £6 million financing round into Cumulus Neuroscience, formerly known as BrainWaveBank. The funding is led by Dementia Discovery Fund (DDF)/SV Health investors and supported by the UK Future Fund.
... |
| 22.12.2020 | LifeArc co-leads £6 million funding in DJS Antibodies | LifeArc announces Seed Fund investment of £2 million in DJS Antibodies, a biotech start-up company pioneering the development of novel antibody therapeutics for inflammatory disease. LifeArc is co-leading the c.£6 million funding with Sedgw... |
| 22.12.2020 | LifeArc co-leads £6 million funding in DJS Antibodies | LifeArc announces Seed Fund investment of £2 million in DJS Antibodies, a biotech start-up company pioneering the development of novel antibody therapeutics for inflammatory disease. LifeArc is co-leading the c.£6 million funding with Sedgw... |
| 23.09.2020 | LifeArc and Future Fund provide £3.0m in funding to Avvinity Therapeutics | LifeArc, an independent medical research charity, announces a £3.0m co-investment in British biotech Avvinity Therapeutics alongside the UK government’s Future Fund. Lead investor LifeArc leveraged £1.5m of seed funding provided to Avvinity... |
| 23.09.2020 | LifeArc and Future Fund provide £3.0m in funding to Avvinity Therapeutics | LifeArc, an independent medical research charity, announces a £3.0m co-investment in British biotech Avvinity Therapeutics alongside the UK government’s Future Fund. Lead investor LifeArc leveraged £1.5m of seed funding provided to Avvinity... |
| 29.08.2019 | LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases | LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases based on original work. Focusing on ... |
| 29.08.2019 | LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases | LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases based on original work. Focusing on ... |
| 14.06.2019 | LifeArc invests £1.5 million in Ducentis BioTherapeutics | 14 June 2019: LifeArc, a UK-based medical research charity, has made a £1.5 million investment in Ducentis BioTherapeutics from its Seed Fund to develop novel therapies for the treatment of autoimmune disease. These monies will fund pre-cli... |
| 14.06.2019 | LifeArc invests £1.5 million in Ducentis BioTherapeutics | 14 June 2019: LifeArc, a UK-based medical research charity, has made a £1.5 million investment in Ducentis BioTherapeutics from its Seed Fund to develop novel therapies for the treatment of autoimmune disease. These monies will fund pre-cli... |
| - | Clare Terlouw, Head of LifeArc Ventures, talks about the LifeArc co-founded company RQ Bio licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-... | - |
| - | AbCellera and RQ Bio Partner | VANCOUVER, British Columbia & LONDON, March 22, 2023 – AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease ... |
| - | LifeArc Ventures Investment Principal, Chris Baker, reflects on the highlights from AUTM23 | The AUTM conference was the first society/association event I’ve attended where diversity and inclusion were being addressed so effectively. Refreshingly, the conversation has progressed from simple numbers to people actively feeling empowe... |
| - | LifeArc portfolio company RQ Bio’s antibody enters clinical trials | LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients, AZD3152, has entered clinical trials – less than 12 months after discovery... |
| - | International Women’s Day | We’re lucky to have such remarkable women on board and are grateful for their dedication. Today is a day of celebration, and this year’s #IWD2023 theme focuses on embracing equity both in and out of the workplace.
Hear from some of our ext... |
| - | Kovilen Sawmynaden, Senior Principal Scientist at LifeArc, explains the science behind RQ Bio’s monoclonal antibodies against SARS-CoV-2 – | - |
